A5033749010- Multiple Sclerosis Research Studies
- Lymphadenopathy Diagnosis and Analysis
- Peripheral Neuropathies and Disorders
- COVID-19 and healthcare impacts
- Systemic Sclerosis and Related Diseases
- Viral Infections and Vectors
- SARS-CoV-2 and COVID-19 Research
- Autoimmune Bullous Skin Diseases
- Rheumatoid Arthritis Research and Therapies
- Cervical Cancer and HPV Research
Royal Hobart Hospital
2022
The Royal Melbourne Hospital
2020-2021
Background The Greater Hobart region (42.5°S) of Tasmania has consistently had the highest recorded prevalence and incidence rates multiple sclerosis (MS) in Australia. We reassessed MS epidemiology 2009–2019 assessed longitudinal changes over 68 years. Methods Cases recruited from clinic-based datasets other data sources. 2019 annual mortality estimated, differences using Poisson regression. Results 436 cases resident on day were identified, 130 symptom onset within 2009–2019. Prevalence...
<h3>Background</h3> The Greater Hobart region (42.5°S) of Tasmania has consistently had the highest recorded prevalence and incidence rates MS in Australia. We re-assessed epidemiology 2009–2019 assessed longitudinal changes over 68 years. <h3>Methods</h3> Cases recruited from clinic-based datasets multiple other data sources. 2019 2009–19 annual mortality estimated, differences using Poisson regression. <h3>Results</h3> 436 cases resident on day were identified. Prevalence 197.1/100,000...
<h3>Objective</h3> To examine factors determining risk of self-reported infections and antimicrobial use in patients receiving Ocrelizumab for MS. <h3>Methods</h3> Retrospective, observational cohort study conducted Ocrelizumab-treated at the Royal Melbourne Hospital. The association clinical laboratory with infection rate were estimated using univariate multivariable logistic regression models. <h3>Results</h3> 185 included study, 176 reported 89 (46.1%), 47 (25.3%) was identified. In...